Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GFH009 Monotherapy in Relapsed or Refractory PTCL
NCT05934513Phase 2Recruiting
- Sponsor
- GenFleet Therapeutics
- Start
- Sep 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of GFH009 in peripheral T-cell lymphoma (PTCL), sponsored by GenFleet Therapeutics. Started Sep 2023; status: recruiting.
02
Drugs
GFH009
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT05934513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05934513.